Acute Relief Of Angina Pectoris Due To Coronary Artery Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute relief of angina pectoris due to coronary artery disease. 2 active patents protecting 1 drugs from 0+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
2
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Acute Relief Of Angina Pectoris Due To Coronary Artery Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute relief of angina pectoris due to coronary artery disease. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
29
1
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
NITROGLYCERIN — 2 64 — 2029-03-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7872049 NITROGLYCERIN method of use 80 2029-03-12
9101592 NITROGLYCERIN formulation 48 2032-03-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9101592 NITROGLYCERIN formulation 48 2032-03-11
7872049 NITROGLYCERIN method of use 80 2029-03-12

Related